|Videos|April 4, 2017

Should Patients Take a Complete Course of Antibiotics? The Debate Ensues

Lauri A. Hicks, DO, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, explains an area of debate in the general medical field regarding antibiotics.

Lauri A. Hicks, DO, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, explains an area of debate in the general medical field regarding antibiotics.

Interview Transcript (slightly modified for readability)

“One of the challenges with talking to patients about taking a complete course of antibiotics is that (in dentistry in particular) we really don’t know what the optimal duration of therapy is for a lot of dental conditions. In some instances, it may be better for the patient not to receive an antibiotic at all.

This is an area of debate right now in the general medical field with respect to antibiotics. There’s a lot of debate about whether taking the full course of antibiotics is better, or whether taking the antibiotic until you feel better is the best course of action. I think what is needed is studies to shed light on what the optimal duration of therapy is for each and every condition that we treat with antibiotics.”


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.